Drug Trial Radar · NCT06645197
An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
Last checked: Nov 19, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
7
Planned (sponsor's estimate)
Start
Oct 16, 2024
Primary completion
Apr 15, 2025
Study completion Oct 15, 2029
Sponsor
- Lead sponsor
- Peking University Third HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- SineuGene Therapeutics Co., Ltd.
- First posted
- Oct 16, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, single-arm investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of SNUG01 in patients with Amyotrophic Lateral Sclerosis (ALS).
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
SNUG01Drug
Recombinant adeno-associated virus serotype 9 capsid containing human SG001 expression cassette
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of ascending doses of intrathecally administered SNUG01 in Participants with ALSTime frame: Each visit in 1 year after administration
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China
Fujian Medical University Union Hospital
Fujian, Fuzhou, China
JiangSu Provincce Hospital
Nanjing, Jiangsu, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.